Trump Launches TrumpRx.gov With Promises of Lower Drug Prices

President Trump unveiled TrumpRx.gov with drugmakers agreeing to sell many medicines at “most favored nation” prices, promising quick savings for patients.

Story Highlights

The White House launched TrumpRx.gov to sell drugs at lower, internationally benchmarked prices.
Early agreements included major manufacturers and expanded over several months.
Reuters reported commitments to lower prices for Medicaid and cash buyers, tied to tariff relief.
The administration reported hundreds of millions in consumer savings to date.

What The White House Announced And How It Works

The White House said TrumpRx.gov would let Americans buy dozens of common drugs at lower prices starting the night of the launch. President Trump said patients would see “dramatic discounts,” and the site would expand access as more deals closed. The administration framed the pricing as “most favored nation” terms, which peg U.S. prices to the lowest paid in peer countries. The site is meant to offer clear prices and a direct way to buy or enroll in company discount programs.

The initial rollout listed five companies: AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer. Later, the White House said it had reached the seventeenth such agreement with Regeneron, reflecting a broader push across brand and biotech firms. Officials also said more than 600 generic drugs would be offered through the portal as the program scaled, making everyday medicines easier to compare and purchase at posted discount prices.

What Drugmakers Agreed To Provide

Reuters reported that companies including Pfizer, Eli Lilly, and Amgen agreed to cut prices for the Medicaid program and for people paying cash. Those commitments included selling through TrumpRx.gov at most favored nation prices, plus making new investments in U.S. operations. In return, the government granted three-year tariff exemptions, which the reporting described as part of the overall deal structure. The White House presented these steps as voluntary agreements with multiple manufacturers.

The administration’s materials said the approach tackles a long-running problem: high list prices and hidden rebates that do not always lower what patients pay at the counter. By tying prices to international benchmarks and offering direct purchase routes, officials said patients could avoid some layers that add cost. That frame fits years of debate over list prices, rebates to pharmacy benefit managers, and gaps between headline cuts and real out-of-pocket savings.

What Savings Officials Claim So Far

White House statements in August said the initiative had already produced about seven hundred million dollars in savings for millions of patients. Those releases also promoted the launch as a major shift in drug pricing policy, with claims of large list price drops across several categories. Reporters noted that participation has grown but is not universal, and that different programs—brand-name deals, generics on the portal, and later company agreements—advanced on separate tracks over time.

Prescription drug prices have dropped based on the inflation reduction act that was passed during the Biden administration in 2022.

It went into effect in January 2026…

Mike Johnson, ask not what you can do for your country… instead ask what Trump can take credit for that…

— Alene Browdy (@diagirl00491) September 1, 2026

For people left out of the old system, the practical stakes are clear. Many families have watched drug bills rise while wages lag. Seniors fear rationing medicines to stretch budgets. Small-business owners struggle to offer health plans. The TrumpRx push tries to meet those pain points with posted prices and direct access. At the same time, coverage decisions by insurers and pharmacy benefit managers still shape what many insured patients pay, which can blunt how fast savings spread.

What This Means For Everyday Patients And Taxpayers

Patients who pay cash, face high deductibles, or take drugs on the portal’s list are most likely to feel the cuts first. Medicaid programs could also gain from lower purchase prices if agreements hold at scale. People whose plans steer them to other products may see slower change. The White House urged Congress to lock in the framework, signaling the policy depends on continued executive action and company compliance while deals expand across more drugs.